ArticleAnalytical and bioanalytical chemistry2026
5-Methyl etodesnitazene human metabolism: LC-ESI
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid emergence of new synthetic opioids (NSOs), especially potent 2-benzylbenzimidazole derivatives known as nitazenes, poses challenges to public health and toxicologists. Among these substances, 5-methyl etodesnitazene has recently appeared on the illicit market. This compound was shown to be approximately twice as potent as fentanyl at the µ-opioid receptor, and overdose may lead to potentially fatal respiratory depression. Detecting the drug and its metabolites is therefore critical for clinical and forensic investigations. This study aimed to characterize the metabolic profile of 5-methyl etodesnitazene in humans. Metabolic transformations were investigated through incubations with ten-donor pooled human hepatocytes and analysis of blood and urine samples from a postmortem case positive for 5-methyl etodesnitazene. Samples were analyzed using liquid chromatography-electrospray ionization-high-resolution tandem mass spectrometry (LC-ESI-HRMS/MS) in positive- and negative-ionization modes, and software-aided data mining. In positive mode, 5-methyl etodesnitazene produced an intense signal in its di-protonated form, which generated informative spectra, facilitating structural elucidation. Biotransformations included N- and O-deethylation, consistent with structural analogs, as well as ω-carboxylation specific to the methylated benzimidazole core; phase II metabolites were not detected. We suggest N-deethyl-5-methyl etodesnitazene, N-deethyl-5-carboxy etodesnitazene, and 5-carboxy etodesnitazene in blood, and N-deethyl-5-carboxy-4'-hydroxy etodesnitazene, 5-carboxy-4'-hydroxy etodesnitazene, and N-deethyl-5-carboxy etodesnitazene in urine, as metabolite biomarkers of consumption in clinical and forensic settings. Overall, metabolite profiles were consistent across in vitro and in vivo data, with minor matrix-specific differences. Considering that nitazene metabolites are often active and their metabolism is susceptible to genetic polymorphism, further research on the pharmacokinetics and pharmacodynamics of 5-methyl etodesnitazene is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.